1.3.5.2: dihydroorotate dehydrogenase (quinone)
This is an abbreviated version!
For detailed information about dihydroorotate dehydrogenase (quinone), go to the full flat file.
Word Map on EC 1.3.5.2
-
1.3.5.2
-
pyrimidine
-
falciparum
-
plasmodium
-
leflunomide
-
brequinar
-
uridine
-
malaria
-
arthritis
-
antimalarial
-
rheumatoid
-
dihydroorotase
-
salvage
-
teriflunomide
-
dhods
-
autoimmune
-
orotidine
-
ump
-
atovaquone
-
triazolopyrimidine
-
flavoenzyme
-
medicine
-
phosphoribosyltransferase
-
antirheumatic
-
coq
-
drug development
-
decylubiquinone
-
dmards
-
synthesis
-
species-selective
-
pyre
-
pharmacology
-
isoxazole
-
transcarbamoylase
-
5-fluoroorotate
- 1.3.5.2
- pyrimidine
- falciparum
- plasmodium
- leflunomide
- brequinar
- uridine
- malaria
- arthritis
-
antimalarial
-
rheumatoid
- dihydroorotase
-
salvage
- teriflunomide
-
dhods
- autoimmune
- orotidine
- ump
- atovaquone
- triazolopyrimidine
-
flavoenzyme
- medicine
-
phosphoribosyltransferase
-
antirheumatic
- coq
- drug development
- decylubiquinone
-
dmards
- synthesis
-
species-selective
-
pyre
- pharmacology
-
isoxazole
-
transcarbamoylase
- 5-fluoroorotate
Reaction
Synonyms
class 2 dihydroorotate dehydrogenases, DHO-DH, DHOD, DHODase, DHODH, dihydroorotate dehydrogenase, EC 1.3.99.11, ETH_00004975, hDHODH, HsDHODH, L-5,6-dihydroorotate:ubiquinone exidoreductase, PfDHODH
ECTree
1.3.5.2 dihydroorotate dehydrogenase (quinone)Advanced search results
results (
results (Inhibitors
Inhibitors on EC 1.3.5.2 - dihydroorotate dehydrogenase (quinone)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(1-(5-cyclopropylpyrimidin-2-yl)-3-isopropoxy-5-methyl-1H-pyrazol-4-yl)(phenyl)methanol
Q02172
-
(2,3-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(2,5-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(2,6-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(2-chloro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(2-fluoro-4-methyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(2E)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
-
50% inhibition at 0.000435 mM
(2E)-2-cyano-N-(2',3-dichloro[1,1'-biphenyl]-4-yl)-3-hydroxybut-2-enamide
-
-
(2E)-N-(3-chloro-2'-methoxy[1,1'-biphenyl]-4-yl)-2-cyano-3-hydroxybut-2-enamide
-
-
(2E)-N-[2'-chloro-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-cyano-3-hydroxybut-2-enamide
-
-
(3,4-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3,4-dimethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3,5-bis-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3,5-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3-chloro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3-fluoro-4-methyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3-fluoro-4-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(3-fluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-benzyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-bromo-3-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-bromo-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-chloro-3-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-chloro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-difluoromethoxy-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-fluoro-3-methyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-fluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(4-methoxyphenyl)(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,3,4,5,6-pentafluorophenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,3,4-trifluoro-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,3,5,6-tetrafluoro-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,4,5-trifluoro-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,4,6-trifluoro-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2-trifluoromethyl-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(3-trifluoromethyl-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-methyl-3-trifluoromethylphenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-nitro-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-trifluoromethoxy-phenyl)-amine
-
-
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-trifluoromethyl-phenyl)-amine
-
DSM74
(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-yl-amine
-
DSM1, a potent triazolopyrimidine-based inhibitor of PfDHODH that shows greater than 4000fold selectivity for the malarial enzyme when compared to human DHODH
1-(1-naphthyl)-3-[2-(trifluoromethyl)phenyl]urea
-
50% inhibition at 0.0004 mM, wild type, 0.00034 mM, mutant R265A, above 0.2, mutant H185A
1-(2-((4-bromo-3-(trifluoromethyl)phenyl)amino)-4-methylthiazol-5-yl)ethanone
Q02172
-
1-(2-((4-chloro-3-(trifluoromethyl)phenyl)amino)-4-methylthiazol-5-yl)ethanone
Q02172
-
1-(2-methoxyphenyl)-3-(1-naphthyl)urea
-
50% inhibition at 0.00023 mM, wild type, 0.00024 mM, mutant R265A, 0.140, mutant H185A
1-(4-chlorophenyl)-3-quinolin-8-ylurea
-
50% inhibition at 0.00078 mM, wild type, 0.002 mM, mutant R265A, above 0.4, mutant H185A
1-hydroxy-2-dodecyl-4(1)quinolone
-
competitive with regard to decylubiquinone, uncompetitive with regard to dihydroorotate
10-phenyl-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
2,8-dimethyl-N-[4-(trifluoromethyl)phenyl]pyrrolo[1,2-a]pyrimidin-4-amine
-
-
2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-lambda6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid
-
-
2-(3-ethoxy-4-(2-fluorophenoxy)-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(3-ethoxy-5-methyl-4-(2-(trifluoromethyl)phenoxy)-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(3-ethoxy-5-methyl-4-(3-(trifluoromethyl)phenoxy)-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(3-ethoxy-5-methyl-4-(4-(trifluoromethyl)phenoxy)-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4'-tert-butyl-2-chloro-biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid
-
50% inhibition at 0.000080 mM
2-(4-(2,3-dichlorophenoxy)-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2,3-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2,4-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2,5-dichlorophenoxy)-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2,5-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidin-4-ol
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-fluoropyrimidine
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-methoxypyrimidine
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-4-ol
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-propylpyrimidin-4-ol
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-propylpyrimidine
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-pyrimidine
Q02172
-
2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidin-4-ol
Q02172
-
2-(4-(2-(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-carboxylic acid
-
-
2-(4-(2-bromophenoxy)-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-methyl-1,7-naphthyridine-4-carboxylic acid
-
-
2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid
-
-
2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)quinoline-4-carboxylic acid
-
-
2-(4-(2-chlorophenoxy)-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(2-chloropyridin-3-yl)phenyl)-3,6-dimethylquinoline-4-carboxylic acid
-
-
2-(4-(2-chloropyridin-3-yl)phenyl)-3-methyl-1,7-naphthyridine-4-carboxylic acid
-
-
2-(4-(2-chloropyridin-3-yl)phenyl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid
-
-
2-(4-(2-chloropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
2-(4-(2-chloropyridin-3-yl)phenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid
the compound possesses significant oral bioavailability (F = 56%) and an elimination t1/2 = 2.78 h, pharmacokinetic parameters, overview
-
2-(4-(2-fluoro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
2-(4-(2-fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
2-(4-(3,5-dichlorophenoxy)-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-(4-(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-carboxylic acid
-
-
2-(4-benzyl-1-(5-ethylpyrimidin-2-yl)-5-methyl-1H-pyrazol-3-yloxy)ethanol
Q02172
-
2-(4-benzyl-3-(2-(benzyloxy)ethoxy)-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine
Q02172
-
2-(4-benzyl-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-cyclopropylpyrimidine
Q02172
-
2-(4-benzyl-3-methoxy-5-methyl-1H-pyrazol-1-yl)-5-cyclopropylpyrimidine
Q02172
-
2-(4-benzyl-3-sec-butoxy-5-methyl-1H-pyrazol-1-yl)-5-cyclopropylpyrimidine
Q02172
-
2-(4-benzyl-5-methyl-3-(pentan-3-yloxy)-1H-pyrazol-1-yl)-5-cyclopropylpyrimidine
Q02172
-
2-(4-biphenylylcarbamoyl)-2-benzoic acid
i.e. MD 129, 0.5 mM, 95% of initial activity
-
2-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-benzonitrile
-
-
2-([1,1'-biphenyl]-4-yl)-3-methyl-1,6-naphthyridine-4-carboxylic acid
-
-
2-([1,1'-biphenyl]-4-yl)-3-methyl-1,7-naphthyridine-4-carboxylic acid
-
-
2-([1,1'-biphenyl]-4-yl)-3-methyl-1,8-naphthyridine-4-carboxylic acid
-
-
2-([1,1'-biphenyl]-4-yl)-3-methyl-6-(trifluoromethyl)-1,7-naphthyridine-4-carboxylic acid
-
-
2-([[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000007 mM
2-([[2-chloro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000020 mM
2-([[2-chloro-4'-(dimethylamino)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00005 mM
2-([[3'-(trifluoromethoxy)-3-(trifluoromethyl)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000840 mM
2-([[3,5-difluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000033 mM
2-([[3-chloro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000290 mM
2-([[3-cyano-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000370 mM
2-([[3-fluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00028 mM
2-([[3-fluoro-4'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00570 mM
2-([[3-methyl-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000150 mM
2-([[3-nitro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000390 mM
2-([[4'-(dimethylamino)-3,5-difluorobiphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00061 mM
2-([[4-(1-naphthyl)-2-(trifluoromethyl)phenyl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000180 mM
2-hydroxyethylidene-cyano acetic acid 4-trifluoromethyl anilide
-
A177-1726, active derivative of human inhibitor leflunomide
2-methyl-3-nitro-N-[3-(trifluoromethyl)phenyl]benzamide
-
50% inhibition at 0.00008 mM, wild type, 0.00037 mM, mutant R265A, 0.120, mutant H185A
2-methyl-N-1-naphthyl-3-nitrobenzamide
-
50% inhibition at 0.00008 mM, wild type, 0.00048 mM, mutant R265A, 0.180, mutant H185A
2-[(biphenyl-4-ylamino)carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00041 mM
2-[[(2',3,5-trifluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000045 mM
2-[[(2'-chloro-3,5-difluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000018 mM
2-[[(2'-chlorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000225 mM
2-[[(2,3,5,6-tetrafluoro-2'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000008 mM
2-[[(3'-ethoxy-3,5-difluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000017 mM
2-[[(3,3'-dimethoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000170 mM
2-[[(3,5-difluoro-2',4'-dimethoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000090 mM
2-[[(3,5-difluoro-2'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000042 mM
2-[[(3-chloro-2'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000310 mM
2-[[(3-chloro-4'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00840 mM
2-[[(3-fluoro-3'-hydroxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000610 mM
2-[[(3-fluoro-4'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.00170 mM
2-[[(4'-bromo-2-chlorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000070 mM
2-[[(4'-bromo-3-chlorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.002900 mM
2-[[(4'-bromo-3-fluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid
-
50% inhibition at 0.000735 mM
2-[[(4-chlorophenyl)methyl]sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one
-
-
3-(3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazol-9-yl)phenol
IC50 value for human enzyme above 0.0045 mM
-
3-(3-methylbut-2-en-1-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl 4-methylbenzene-1-sulfonate
-
3-(4-benzyl-1-(5-ethylpyrimidin-2-yl)-5-methyl-1H-pyrazol-3-yloxy)-N,N-dimethylpropan-1-amine
Q02172
-
4-(3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazol-9-yl)phenol
IC50 value for human enzyme above 0.0045 mM
-
4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-2-trifluoromethylbenzonitrile
-
-
4-(6-imino-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-9-yl)benzamide
IC50 value for human enzyme above 0.0045 mM
-
4-[(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]-2-(trifluoromethyl)benzonitrile
-
5-(4-cyano-2-methyl-1H-benzimidazol-1-yl)-N-cyclopropylthiophene-2-carboxamide
-
-
5-bromo-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-cyclopropyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-cyclopropyl-2-(4-(2-fluorobenzyl)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(3-isopropoxy-4-(2-methoxybenzyl)-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(3-isopropoxy-4-(3-methoxybenzyl)-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(3-isopropoxy-4-(4-methoxybenzyl)-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(4-(2-fluorobenzyl)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(4-(2-fluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(4-(3-fluorobenzyl)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(4-(3-fluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(4-(4-fluorobenzyl)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-ethyl-2-(4-(4-fluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-methyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine
Q02172
-
5-methyl-N-(2,3,4-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-(2,4,5-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-(3-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-(4-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-(4-nitrophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-[4-(trifluoromethoxy)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-[4-methyl-3-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
6-chloro-2-(4-(2-chloro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
6-chloro-2-(4-(2-chloropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
6-chloro-2-(4-(2-fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid
-
6-fluoro-2-(4-(2-fluoro-6-methylpyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
6-fluoro-2-(4-(2-fluoropyridin-3-yl)phenyl)-3-methylquinoline-4-carboxylic acid
-
-
6-fluoro-2-[2-methyl-4-phenoxy-5-(propan-2-yl)phenyl]quinoline-4-carboxylic acid
i.e. C44
-
8-(1,3,3a,4-tetrahydro-2-benzofuran-4-yl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
8-(1,8a-dihydronaphthalen-1-yl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
8-(oxolan-2-yl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
8-(pyridin-3-yl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
8-(thiolan-3-yl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
9-(1-benzofuran-2-yl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(2,3-dihydro-1,4-benzodioxin-6-yl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(2-methoxyphenyl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
9-(2-nitrophenyl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
9-(2H-1,3-benzodioxol-5-yl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(3-ethylphenyl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(4-nitrophenyl)-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
9-(4-phenoxyphenyl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(isoquinolin-6-yl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(naphthalen-1-yl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-(naphthalen-2-yl)-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-phenyl-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-phenyl-3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazole
IC50 value for human enzyme above 0.0045 mM
-
9-[(E)-2-phenylethenyl]-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-[3-[(propan-2-yl)oxy]phenyl]-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-[4-(methylsulfanyl)phenyl]-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
9-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
IC50 value for human enzyme above 0.0045 mM
-
biphenyl-4-yl-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine
-
-
diethyl [(5a,9a-dihydrodibenzo[b,d]thiophen-2-ylamino)methylidene]propanedioate
-
ethyl 2-((2,3-dihydro-1h-inden-5-yl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3'-methoxy-[1,1'-biphenyl]-4-yl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3,5-difluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)-amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-chloro-4-((2-chloro-6-fluorobenzyl)oxy)phenyl)-amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-chloro-4-methylphenyl)amino)-4-cyclopropylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-chloro-4-methylphenyl)amino)-4-methylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-chloro-4-methylphenyl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-chloro-4-phenoxyphenyl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-fluoro-4-methylphenyl)amino)-4-methylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-fluoro-4-methylphenyl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((3-fluoro-[1,1'-biphenyl]-4-yl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((4-(benzyloxy)-3-chlorophenyl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((4-bromo-3-(trifluoromethyl)phenyl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 2-((4-chloro-3-(trifluoromethyl)phenyl)amino)-4-(cyclopropanecarboxamido)thiazole-5-carboxylate
Q02172
-
ethyl 2-((4-chloro-3-(trifluoromethyl)phenyl)amino)-4-phenylthiazole-5-carboxylate
Q02172
-
ethyl 4-(cyclopropanecarboxamido)-2-((3,4-dimethylphenyl)amino)thiazole-5-carboxylate
Q02172
-
ethyl 4-(tert-butyl)-2-((3,4-dimethylphenyl)amino)thiazole-5-carboxylate
Q02172
-
ethyl 4-(tert-butyl)-2-((3-chloro-4-methylphenyl)amino)-thiazole-5-carboxylate
Q02172
-
ethyl 4-(tert-butyl)-2-((3-fluoro-4-methylphenyl)amino)-thiazole-5-carboxylate
Q02172
-
ethyl 4-amino-2-((4-chloro-3-(trifluoromethyl)phenyl)-amino)thiazole-5-carboxylate
Q02172
-
ethyl 4-benzamido-2-((4-chloro-3-(trifluoromethyl)phenyl)-amino)thiazole-5-carboxylate
Q02172
-
ethyl 4-cyclopropyl-2-((3,4-dimethylphenyl)amino)thiazole-5-carboxylate
Q02172
-
ethyl 4-cyclopropyl-2-((4-fluoro-3-methylphenyl)amino)-thiazole-5-carboxylate
Q02172
-
ethyl 4-phenyl-2-((4-(trifluoromethyl)phenyl)amino)-thiazole-5-carboxylate
Q02172
-
ethyl 4-phenyl-2-((5,6,7,8-tetrahydronaphthalen-2-yl)-amino)thiazole-5-carboxylate
Q02172
-
methyl 2-(4-(4-(trifluoromethyl)pyridin-3-yl)phenyl)quinoline-4-carboxylate
-
-
methyl 3-(3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazol-9-yl)benzoate
IC50 value for human enzyme above 0.0045 mM
-
methyl 4-(3,4-dihydro-2H-pyrimido[1,2-b][1,2]benzothiazol-9-yl)benzoate
IC50 value for human enzyme above 0.0045 mM
-
methyl 4-(6-imino-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-9-yl)benzoate
IC50 value for human enzyme above 0.0045 mM
-
N-(2,3-difluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(2,4-dichlorophenyl)-2-naphthamide
-
50% inhibition at 0.00005 mM, wild type, 0.00008 mM, mutant R265A, above 0.05, mutant H185A
N-(2-fluoro-4-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(2-fluorophenyl)-2-naphthamide
-
50% inhibition at 0.00047 mM, wild type, 0.00030 mM, mutant R265A, 0.21, mutant H185A
N-(3,4-dichlorophenyl)-2-methyl-3-nitrobenzamide
-
50% inhibition at 0.00008 mM, wild type, 0.0028 mM, mutant R265A, 0.06, mutant H185A
N-(3,4-difluorophenyl)-2-methyl-3-nitrobenzamide
-
50% inhibition at 0.00026 mM, wild type, 0.00082 mM, mutant R265A, 0.25, mutant H185A
N-(3,4-difluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(3,4-dimethylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(3,5-difluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(3-bromophenyl)-2-methyl-3-nitrobenzamide
-
50% inhibition at 0.00006 mM, wild type, 0.0012 mM, mutant R265A, 0.140, mutant H185A
N-(3-chloro-4-fluorophenyl)-2-methyl-3-nitrobenzamide
-
50% inhibition at 0.0001 mM, wild type, 0.0005 mM, mutant R265A, 0.13, mutant H185A
N-(3-fluoro-4-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(4-benzylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(4-bromo-2-methylphenyl)-2-naphthamide
-
50% inhibition at 0.00005 mM, wild type, 0.00005 mM, mutant R265A, 0.57, mutant H185A
N-(4-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(4-fluoro-3-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(4-methoxyphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(biphenyl-4-yl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM2
N-cyclopropyl-5-[4-(difluoromethoxy)-2-methyl-1H-benzimidazol-1-yl]thiophene-2-carboxamide
-
-
N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-[4-(difluoromethoxy)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-[4-bromo-3-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
trifluoromethyl 6-(6-imino-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-9-yl)-1H-indole-3-carboxylate
IC50 value for human enzyme above 0.0045 mM
-
[2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy)pyridin-3-yl]biphenyl-4-yl]-(3-methyl-2-butenyl)amine
[4-(6-imino-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-9-yl)phenyl](4-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)methanone
IC50 value for human enzyme above 0.0045 mM
-
(2Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[4-(trifluoromethyl)phenyl]prop-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[4-(trifluoromethyl)phenyl]prop-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(2',3-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(2',3-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(2,3'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(2,3'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-N-(2'-chlorobiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-N-(2'-chlorobiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
(2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
(2Z)-N-[2'-chloro-3-(trifluoromethyl)biphenyl-4-yl]-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
(2Z)-N-[2'-chloro-3-(trifluoromethyl)biphenyl-4-yl]-2-cyano-3-hydroxybut-2-enamide
inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
-
1,4-benzoquinone
3.9fold selectivity for Schistosoma mansoni over human enzyme
1,4-benzoquinone
3.9fold selectivity for Schistosoma mansoni over human enzyme
2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-lambda6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM265
-
2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-lambda6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM265
-
2-(2,3-dichloroanilino)-3-hydroxynaphthalene-1,4-dione
6.5fold selectivity for Schistosoma mansoni over human enzyme
-
2-(2,3-dichloroanilino)-3-hydroxynaphthalene-1,4-dione
6.5fold selectivity for Schistosoma mansoni over human enzyme
-
2-(2-chloroanilino)-3-hydroxynaphthalene-1,4-dione
10.4fold selectivity for Schistosoma mansoni over human enzyme
-
2-(2-chloroanilino)-3-hydroxynaphthalene-1,4-dione
10.4fold selectivity for Schistosoma mansoni over human enzyme
-
2-(3-chloroanilino)-3-hydroxynaphthalene-1,4-dione
7fold selectivity for Schistosoma mansoni over human enzyme
-
2-(3-chloroanilino)-3-hydroxynaphthalene-1,4-dione
7fold selectivity for Schistosoma mansoni over human enzyme
-
2-(4-biphenylylcarbamoyl)-1-cyclopentene-1-carboxylic acid
i.e. MD 108, 0.5 mM, 23% of initial activity
-
2-(4-biphenylylcarbamoyl)-1-cyclopentene-1-carboxylic acid
i.e. MD 108, 0.5 mM, 90% of initial activity
-
2-(4-chloroanilino)-3-hydroxynaphthalene-1,4-dione
2.9fold selectivity for Schistosoma mansoni over human enzyme
-
2-(4-chloroanilino)-3-hydroxynaphthalene-1,4-dione
2.9fold selectivity for Schistosoma mansoni over human enzyme
-
2-(4-fluoroanilino)-3-hydroxynaphthalene-1,4-dione
3fold selectivity for human over Schistosoma mansoni enzyme
-
2-(4-fluoroanilino)-3-hydroxynaphthalene-1,4-dione
3fold selectivity for human over Schistosoma mansoni enzyme
-
2-cyano-3-(9-ethyl-9H-carbazol-3-ylamino)acrylic acid ethyl ester
-
IC50: 0.491 mM
2-cyano-3-(9-ethyl-9H-carbazol-3-ylamino)acrylic acid ethyl ester
IC50: 0.00044 mM
2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(cyano)phenyl]-propenamide
-
50% inhibition at 0.0.00035 mM, N-terminally truncated protein
2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(cyano)phenyl]-propenamide
50% inhibition at 0.712 mM, N-terminally truncated protein
2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(nitro)phenyl]-propenamide
-
50% inhibition at 0.00025 mM, N-terminally truncated protein
2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(nitro)phenyl]-propenamide
50% inhibition at 0.543 mM, N-terminally truncated protein
2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(trifluoromethyl)phenyl]-propenamide
-
50% inhibition at 0.00019 mM, N-terminally truncated protein
2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(trifluoromethyl)phenyl]-propenamide
50% inhibition at 1.08 mM, N-terminally truncated protein
2-hydroxy-3-(3-methylbutyl)naphthalene-1,4-dione
30.8fold selectivity for Schistosoma mansoni over human enzyme
-
2-hydroxy-3-(3-methylbutyl)naphthalene-1,4-dione
30.8fold selectivity for Schistosoma mansoni over human enzyme
-
2-hydroxy-3-(4-phenylpiperazin-1-yl)naphthalene-1,4-dione
9.6fold selectivity for Schistosoma mansoni over human enzyme
-
2-hydroxy-3-(4-phenylpiperazin-1-yl)naphthalene-1,4-dione
9.6fold selectivity for Schistosoma mansoni over human enzyme
-
2-hydroxy-3-[4-(4-nitrophenyl)piperazin-1-yl]naphthalene-1,4-dione
-
-
2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide
-
anti-proliferative effect of A77 1726 is mediated by inhibition of enzyme
2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide
-
inbibits by interference with the transfer of electrons from flavin to quinone
2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide
-
A77 1726, active metabolite of leflumonide
2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide
-
noncompetitive versus ubiquinone, uncompetitive versus dihydroorotate, study of kinetics
2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3-hydroxynaphthalene-1,4-dione
2fold selectivity for human over Schistosoma mansoni enzyme
-
2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3-hydroxynaphthalene-1,4-dione
2fold selectivity for human over Schistosoma mansoni enzyme
-
2-[(2,5-dichlorophenyl)sulfanyl]-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
compound has therapeutically relevant activity against human enzyme
2-[(2,5-dichlorophenyl)sulfanyl]-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
-
no specific inhibition of Plasmodium enzyme, good inhibitor of human enzyme
2-[(2,5-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
compound has therapeutically relevant activity against human enzyme
2-[(2,5-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
-
no specific inhibition of Plasmodium enzyme, good inhibitor of human enzyme
2-[(2H-1,3-benzodioxol-5-yl)amino]-3-hydroxynaphthalene-1,4-dione
-
-
2-[(3,4-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
compound is less active with human enzyme but good inhibitor of Plasmodium falciparum enzyme
2-[(3,4-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
-
-
2-[(4-chlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
compound is less active with human enzyme but good inhibitor of Plasmodium falciparum enzyme
2-[(4-chlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
-
-
2-[4-(2,3-dichlorophenyl)piperazin-1-yl]-3-hydroxynaphthalene-1,4-dione
4.1fold selectivity for Schistosoma mansoni over human enzyme
-
2-[4-(2,3-dichlorophenyl)piperazin-1-yl]-3-hydroxynaphthalene-1,4-dione
4.1fold selectivity for Schistosoma mansoni over human enzyme
-
2-[4-(4-chlorophenyl)piperazin-1-yl]-3-hydroxynaphthalene-1,4-dione
20.3fold selectivity for Schistosoma mansoni over human enzyme
-
2-[4-(4-chlorophenyl)piperazin-1-yl]-3-hydroxynaphthalene-1,4-dione
20.3fold selectivity for Schistosoma mansoni over human enzyme
-
3-(3-methylbut-2-en-1-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl 4-methylbenzene-1-sulfonate
4.0fold selectivity for human over Schistosoma mansoni enzyme
-
3-(3-methylbut-2-en-1-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl 4-methylbenzene-1-sulfonate
4.0fold selectivity for human over Schistosoma mansoni enzyme
-
3-hydroxy-2-(3,3-dichloroallyl)-1,4-naphthoquinone
-
50% inhibition at 0.000065 mM, i. e. dichloroallyl lawsone, N-terminally truncated protein
3-hydroxy-2-(3,3-dichloroallyl)-1,4-naphthoquinone
50% inhibition at 0.220 mM, i. e. dichloroallyl lawsone, N-terminally truncated protein
5,6-dimethyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-(2-methyl-1H-benzimidazol-1-yl)-N-propylthiophene-2-carboxamide
-
5-(2-methyl-1H-indol-1-yl)-N-propylthiophene-2-carboxamide
-
5-ethyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-7-(naphthalen-2-yloxy)[1,2,4]triazolo[1,5-a]pyrimidine
-
5-methyl-7-(naphthalen-2-ylsulfanyl)[1,2,4]triazolo[1,5-a]pyrimidine
-
5-methyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM1
5-methyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
-
5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM74
5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
-
A77 1726
-
inhibits cell growth in multiple myeloma cell lines at clinically achievable concentrations by induction of apoptosis. Inhibition of cell growth is partly due to inhibition of multiple myeloma cell proliferation. A77 1726 shows synergistic and additive activity together with genotoxic agents melphalan, treosulfan, and doxorubicin
A77-1726
-
50% inhibition at 0.00045 mM, wild-type, 0.00033 mM, DELTA2-21 mutant, 0.00031 mM, DELTA22-37 mutant, 0.00036 mM, DELTA2-37 mutant
A77-1726
0.5 mM, 14% of initial activity, inhibits the growth of Phytophthora infestans
atovaquone
-
50% inhibition at 0.000698 mM, wild-type enzyme, 0.000904 mM, DELTA1-29 mutant
atovaquone
6.3fold selectivity for Schistosoma mansoni over human enzyme
brequinar
-
50% inhibition at 0.567 mM, wild-type, 0.528 mM, DELTA2-21 mutant, 0.615 mM, DELTA22-37 mutant, 0.662 mM, DELTA2-37 mutant
brequinar
-
50% inhibition at 0.000367 mM, wild-type enzyme, 0.000127 mM, DELTA1-29 mutant
brequinar
540fold selectivity for human over Schistosoma mansoni enzyme
brequinar sodium
1 mM reduces the activity by more than 50% of the full-length enzyme
brequinar sodium
-
tight binding, most potent inhibitor, mutant H26A is insensitive, wild-type and other mutants are inhibited by 50% at concentrations between 6 and 10 nM
brequinar sodium
-
inbibits by interference with the transfer of electrons from flavin to quinone
brequinar sodium
-
competitive versus ubiquinone, uncompetitive versus dihydroorotate, study of kinetics
brequinar sodium
complete activity termination in all tissues at 0.01 mM
dichloroallyl lawsone
-
50% inhibition at 0.00051 mM, wild-type, 0.00031 mM, DELTA2-21 mutant, 0.00020 mM, DELTA22-37 mutant, 0.00021 mM, DELTA2-37 mutant
diethyl [(dibenzo[b,d]thiophen-2-ylamino)methylidene]propanedioate
-
diethyldicarbonate
-
histidine-selective covalent modifier; histidine-selective modifying agent, dose-dependent
ethyl 4-(4-ethoxybenzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate
-
isolapachol
8.3fold selectivity for Schistosoma mansoni over human enzyme
-
isolapachol
8.3fold selectivity for Schistosoma mansoni over human enzyme
-
Lapachol
5.3fold selectivity for Schistosoma mansoni over human enzyme
N-(2-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(2-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
-
50% inhibition at 0.00002 mM, wild type, 0.0004 mM, mutant R265A, 0.13, mutant H185A
N-(3-chloro-2-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
i.e. MD 209, 0.5 mM, 2% of initial activity
-
N-(3-chloro-2-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
i.e. MD 209, 0.5 mM, 0% of initial activity
-
N-(3-chlorobiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
i.e. MD 241, 0.5 mM, 1% of initial activity
-
N-(3-chlorobiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
i.e. MD 241, 0.5 mM, 87% of initial activity
-
N-(3-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(3-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(4-bromophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(4-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(anthracen-2-yl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-(anthracen-2-yl)-N,5-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-cyclopropyl-5-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)thiophene-2-carboxamide
-
-
N-cyclopropyl-5-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)thiophene-2-carboxamide
-
N-cyclopropyl-5-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)thiophene-2-carboxamide
-
-
N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM190, 0.5 mM, 36% of initial activity
-
N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
i.e. DSM190, 0.5 mM, 38% of initial activity
-
N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
-
N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
-
Orotate
-
also inhibitors: 5-substituted orotates; competitive to dihydroorotate; strong competitive inhibitor
redoxal
0.5 mM exhibit an inhibitory effect of more than 50% on full-length DHODH and N-terminally truncated DHODH compared with the noninhibited reaction
redoxal
-
50% inhibition at 0.029 mM, wild-type, 0.057 mM, DELTA2-21 mutant, 0.040 mM, DELTA22-37 mutant, 0.056 mM, DELTA2-37 mutant
redoxal
50% inhibition at 0.071 mM, N-terminally truncated protein
teriflunomide
160fold selectivity for human over Schistosoma mansoni enzyme
teriflunomide
160fold selectivity for human over Schistosoma mansoni enzyme
[2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy)pyridin-3-yl]biphenyl-4-yl]-(3-methyl-2-butenyl)amine
-
i.e. S-2678, suppresses immunoglobulin production in human peripheral blood mononuclear cells in vitro, with little or no inhibition of cell proliferation
[2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy)pyridin-3-yl]biphenyl-4-yl]-(3-methyl-2-butenyl)amine
-
i.e. S-2678, suppresses immunoglobulin production in mouse B cells in vitro, with little or no inhibition of cell proliferation, probably through inhibition of class switch recombination in the immunoglobulin heavy chain loci in B cells. In vivo antibody production induced by systemic immunization with ovalbumin is dramatically suppressed by oral administration of S-2678, without any toxicological signs. S-2678 does not affect T-cell activation in vitro, and cytokine production induced by intravenous anti-CD3 antibody in mice. S-2678 does not affect host defense in a mouse model of Candida infection, whereas leflunomide severely impaires it
[[3-(3-methylbut-2-en-1-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]oxy]acetonitrile
-
-
[[3-(3-methylbut-2-en-1-yl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]oxy]acetonitrile
-
-
additional information
competitive nature of small molecule inhibitors toward the putative ubiquinone binding site
-
additional information
-
competitive nature of small molecule inhibitors toward the putative ubiquinone binding site
-
additional information
-
DHODH-specific inhibitors with low nanomolar binding affinities bind in the N-terminal hydrophobic channel of dihydroorotate dehydrogenase, the presumed site of ubiquinone binding during oxidation of dihydroorotate to orotate
-
additional information
-
screening for potent inhibitors of PfDHODH and effect on the human enzyme, overview. The compiunds show strong selectivity for the malarial enzyme over that from the human host, inhibition mechanism, overview
-
additional information
synthesis of a series of 2-substituted quinoline-4-carboxylic acids by Doebner reaction starting from freely available protocatechuic aldehyde and vanillin precursors. Human dihydroorotate dehydrogenase (hDHODH) is recognised as a clear molecular target for these heterocycles. All compounds are also tested for their antiproliferative potential against three cancer cells (MCF-7, A549, A375) and one normal cell line (HaCaT) to evaluate the selective cytotoxicity, overview. IC50 for cytotoxicity in in vivo assays. Molecular docking studies
-
additional information
-
synthesis of a series of 2-substituted quinoline-4-carboxylic acids by Doebner reaction starting from freely available protocatechuic aldehyde and vanillin precursors. Human dihydroorotate dehydrogenase (hDHODH) is recognised as a clear molecular target for these heterocycles. All compounds are also tested for their antiproliferative potential against three cancer cells (MCF-7, A549, A375) and one normal cell line (HaCaT) to evaluate the selective cytotoxicity, overview. IC50 for cytotoxicity in in vivo assays. Molecular docking studies
-
additional information
two potential residues, T63 and Y356, suitable for H-bonding interactions, are identified in the brequinar-binding pocket, design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase, overview. Cytotoxicity and bioavalability assays using HCT-116 and MIA PaCa-2 canvcer cells
-
additional information
-
drug screening and identification of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
-
additional information
DHODH-specific inhibitors with low nanomolar binding affinities bind in the N-terminal hydrophobic channel of dihydroorotate dehydrogenase, the presumed site of ubiquinone binding during oxidation of dihydroorotate to orotate
-
additional information
-
DHODH-specific inhibitors with low nanomolar binding affinities bind in the N-terminal hydrophobic channel of dihydroorotate dehydrogenase, the presumed site of ubiquinone binding during oxidation of dihydroorotate to orotate
-
additional information
development and evaluation of triazolopyrimidine-based DHODH inhibitors, overview. Detailed quantitative structure-activity relationship study and molecular docking studies, the 2-methyltriazolopyrimidine ring interacts with some polar and some nonpolar amino acids whereas the substituted phenyl ring binds with a hydrophobic pocket of the enzyme formed by some nonpolar amino acid residues, overview
-
additional information
screening for potent inhibitors of PfDHODH that show strong selectivity for the malarial enzyme over that from the human host. Lead optimization of a triazolopyrimidine-based series, inhibition mechanism, overview
-
additional information
-
screening for potent inhibitors of PfDHODH that show strong selectivity for the malarial enzyme over that from the human host. Lead optimization of a triazolopyrimidine-based series, inhibition mechanism, overview
-
additional information
drug screening and identifictaion of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolarin vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
-
additional information
-
drug screening and identifictaion of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolarin vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
-
additional information
-
identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice, overview
-
additional information
-
drug screening and identification of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
-
additional information
-
not: bathophenathroline, sulfonate, ethylendiaminetetraacetate, cyanide, azide
-
additional information
-
not inhibitory: brequinar, atovaquone, N-(3,5-difluoro-4-(trifluoromethyl)phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
